STOCK TITAN
  1. Home
  2. Sec-filings
  3. SHPH
  4. [Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity

SHPH insider grant: 29,240 RSUs vesting 2026–2028

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Shuttle Pharmaceuticals director Oleh Nabyt was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and is reported with a $0 price. The RSUs vest in three equal installments: one-third on 08/08/2026, one-third on 08/08/2027 and one-third on 08/08/2028. The award is reported as a direct beneficial holding and, if fully vested and converted, would result in receipt of up to 29,240 shares of common stock.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Time‑based RSU grant to a director; appears routine and aimed at long‑term alignment rather than immediate cash compensation.

The grant of 29,240 RSUs to Director Oleh Nabyt is reported as a direct holding and vests in three equal annual tranches beginning one year after the grant date. As disclosed, each RSU converts to one share at a $0 price, indicating a typical equity‑based retention and alignment instrument. There is no indication in the filing of accelerated vesting conditions or performance metrics. From a governance perspective, this is a common board compensation practice and, based on the information provided, carries a neutral impact on shareholder governance dynamics.

TL;DR: Multi‑year vesting RSUs provide retention incentives; dilution impact depends on total outstanding shares (not disclosed here).

The award vests one‑third annually on 08/08/2026, 08/08/2027 and 08/08/2028, creating retention incentives through 2028. The filing specifies that each RSU equals one share if and when settled. The reported $0 price is standard for restricted stock units. The filing does not state the company's total shares outstanding or the proportionate dilution from this grant, so materiality to shareholders cannot be quantified from the provided content.

Insider Nabyt Oleh
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Unit 29,240 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 29,240 shares (Direct)
Footnotes (1)
  1. Each Restricted Stock Unit ("RSU"s) represents the contingent right to receive one share of common stock. One-third of these RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nabyt Oleh
(Last) (First) (Middle)
C/O SHUTTLE PHARMACEUTICALS HOLDINGS
401 PROFESSIONAL DRIVE, SUITE 260
(Street)
GAITHERSBURG MD 20879
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 08/08/2025 A 29,240 (2) (2) Common Stock 29,240 $0 29,240 D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU"s) represents the contingent right to receive one share of common stock.
2. One-third of these RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028.
/s/ Oleh Nabyt 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Shuttle Pharmaceuticals (SHPH) report for insider activity?

Director Oleh Nabyt was granted 29,240 RSUs on 08/08/2025 as reported on the Form 4.

What does each RSU represent in the SHPH Form 4?

Each RSU represents the contingent right to receive one share of common stock, according to the filing.

When do the RSUs granted to Nabyt vest?

The RSUs vest in three equal installments: 08/08/2026, 08/08/2027 and 08/08/2028.

Was there a purchase price for the RSUs in the SHPH grant?

The filing shows a $0 price for the RSUs, consistent with restricted stock unit awards.

Is the reported ownership direct or indirect?

The Form 4 reports the RSU award as a direct beneficial ownership by the reporting person.